Stem Cell Transplantation in Childhood Non-Hodgkin’s Lymphomas

被引:0
作者
Fatma V. Okur
Robert Krance
机构
[1] Center for Cell and Gene Therapy,Texas Children’s Cancer Center
来源
Current Hematologic Malignancy Reports | 2010年 / 5卷
关键词
Pediatric; Non-Hodgkin’s lymphoma; NHL; Children; Stem cell transplantation; Autologous transplantation; Allogeneic transplantation; Conditioning;
D O I
暂无
中图分类号
学科分类号
摘要
Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin’s lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor. Optimal treatment for this group remains a challenge. Dose intensification followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for these patients, but the number of children treated using this approach is relatively small and its effectiveness has been difficult to judge. Moreover, the limited experience is insufficient to define the patient most likely to benefit from transplantation. Likewise, the selection of autologous or allogeneic transplantation and the optimal conditioning regimen are debated. We summarize the current experience for stem cell transplantation in childhood NHL and offer our recommendations.
引用
收藏
页码:192 / 199
页数:7
相关论文
共 193 条
[1]  
Jaglowski SM(2009)Lymphoma in adolescents and young adults Semin Oncol 36 381-418
[2]  
Linden E(1993)Non-Hodgkin’s lymphomas in children [in French] Rev Prat 43 1665-1668
[3]  
Termuhlen AM(1995)Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin-Frankfurt-Münster group J Clin Oncol 13 359-372
[4]  
Flynn JM(1997)Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry data J Clin Oncol 15 509-517
[5]  
Patte C(2002)Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL Bone Marrow Transplant 29 769-775
[6]  
Reiter A(2004)Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood 103 777-783
[7]  
Schrappe M(2005)Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomas J Clin Oncol 23 2240-2247
[8]  
Parwaresch R(2003)Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients J Clin Oncol 21 897-906
[9]  
Majolino I(2003)Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma Bone Marrow Transplant 32 317-324
[10]  
Pearce R(2007)Allogeneic transplantation in lymphoma: current status Haematologica 92 1533-1548